For children with frequently relapsing and corticosteroid-dependent nephrotic syndrome (NS) who are either on alternate day dosing or not taking corticosteroids, daily corticosteroid therapy for 5-7 days is recommended during episodes of upper respiratory tract and other infections to reduce the risk of relapse.[3]Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-276.
https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext
To minimise the risk of osteoporosis, ensure adequate dietary calcium intake, or start calcium supplementation in those with inadequate intake, in all children treated with corticosteroids.[2]Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023 Mar;38(3):877-919.
https://link.springer.com/article/10.1007/s00467-022-05739-3
http://www.ncbi.nlm.nih.gov/pubmed/36269406?tool=bestpractice.com
Vitamin D levels should be assessed in patients with frequently-relapsing or corticosteroid-dependent NS and supplementation guided by serum levels.[2]Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023 Mar;38(3):877-919.
https://link.springer.com/article/10.1007/s00467-022-05739-3
http://www.ncbi.nlm.nih.gov/pubmed/36269406?tool=bestpractice.com
[3]Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-276.
https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext
Live vaccines are generally contraindicated in patients who take daily immunosuppressants.[2]Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023 Mar;38(3):877-919.
https://link.springer.com/article/10.1007/s00467-022-05739-3
http://www.ncbi.nlm.nih.gov/pubmed/36269406?tool=bestpractice.com
Children in the acute nephrotic state are at increased risk for venous and arterial thromboembolic events that disappear when the child achieves remission. Patients and families should be counselled to make them aware of possible risk factors and of the symptoms of thromboembolic complications and physical activity (and avoidance of immobilisation) encouraged.[2]Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023 Mar;38(3):877-919.
https://link.springer.com/article/10.1007/s00467-022-05739-3
http://www.ncbi.nlm.nih.gov/pubmed/36269406?tool=bestpractice.com